Alveolar proteinosis is a rare lung condition where protein-rich material clogs the tiny air sacs in the lungs, making it harder to breathe and lowering oxygen levels in the blood. While the diagnosis can be frightening, modern treatment approaches—ranging from lung washing procedures to newer medications being tested in research studies—offer hope for managing symptoms and improving quality of life.

Understanding Treatment Goals for Alveolar Proteinosis

When someone receives a diagnosis of alveolar proteinosis, the main focus of treatment is to improve breathing function and maintain adequate oxygen levels in the blood. The approach depends heavily on how severe the symptoms are and which form of the disease a person has. Some patients experience only mild problems and may not need immediate intervention, while others struggle with significant shortness of breath that requires active treatment.

The course of this rare lung disease can vary dramatically from person to person. In some cases, the condition may remain stable for years without getting worse. Occasionally, symptoms may even improve on their own without any medical intervention—a phenomenon doctors call spontaneous remission. However, many patients experience gradual worsening over time, making treatment necessary to prevent serious complications like respiratory failure or dangerous lung infections.

Medical societies have established standard treatment protocols based on decades of experience with this rare condition. At the same time, researchers are actively investigating new therapeutic approaches through clinical trials. These studies explore innovative medications and methods that might offer better outcomes or alternatives for patients who don’t respond well to conventional treatments. Understanding both established therapies and emerging options helps patients and their doctors make informed decisions about the best path forward.

Established Treatment Methods

Whole Lung Lavage: The Standard Approach

Since 1963, the primary treatment for alveolar proteinosis has been a procedure called whole lung lavage, often abbreviated as WLL. This technique essentially involves washing out one lung at a time to remove the accumulated surfactant—the protein and fat mixture that has built up inside the air sacs. Think of it as a deep cleaning procedure for the lungs.

The procedure takes place in an operating theater while the patient is under general anesthesia. An anesthesiologist inserts a special breathing tube called a double-lumen endobronchial tube through the patient’s mouth into the windpipe. This specialized tube has two separate channels, allowing doctors to isolate the left and right lungs from each other. This means that one lung can continue breathing with oxygen support while the other lung is being washed.

During the washing phase, doctors pour sterile saline—essentially purified salt water—into the lung being treated. They then drain it back out, repeating this process many times. In some cases, doctors may use between 30 and 40 liters of saline before the fluid comes out clear instead of milky. The entire procedure can take several hours to complete. Once the washing is finished, any remaining fluid is carefully drained, and the patient is monitored closely as they wake up from anesthesia.

Recovery usually happens in stages. Immediately after the procedure, patients often don’t feel much better—possibly due to the lingering effects of anesthesia and small amounts of fluid still present in the air sacs. However, most people notice significant improvement within about 24 hours. They may be discharged from the hospital at this point, or they may stay to prepare for treatment of the second lung. Because each lung must be treated separately, some patients require a second hospital admission a few weeks or months later.

The duration of benefit from whole lung lavage varies considerably. Some patients experience improvement lasting months or even years, while others may need repeat procedures more frequently. Regular monitoring with lung function tests and oxygen level measurements helps doctors determine when another treatment might be necessary.

Supportive Care and Symptom Management

Many patients with alveolar proteinosis need ongoing support to maintain adequate oxygen levels, even between major treatments. Oxygen therapy at home is commonly prescribed for those whose blood oxygen levels drop too low, especially during physical activity or sleep. Portable oxygen concentrators or tanks allow people to maintain their daily activities while ensuring their organs receive enough oxygen.

Preventing infections is a critical aspect of managing this condition. Because the accumulated material in the lungs creates an environment where bacteria and fungi can thrive, patients face higher risks of developing pneumonia and other respiratory infections. Doctors strongly recommend that patients receive annual flu vaccines, pneumonia vaccines, and COVID-19 vaccines. Washing hands frequently and avoiding close contact with sick individuals becomes especially important.

For patients with secondary alveolar proteinosis—where the condition develops because of another underlying disease—treating that primary condition is essential. This might involve managing blood disorders, addressing immune system problems, or removing exposure to toxic dusts or chemicals that triggered the disease. Without addressing the root cause, the lung problem is likely to recur even after successful whole lung lavage.

In the most severe cases where other treatments have failed and lung function continues to decline despite all interventions, lung transplantation may be considered. This option is typically reserved for patients with advanced disease and life-threatening respiratory failure. The decision to pursue transplantation involves careful evaluation by a specialized medical team and consideration of many factors, including overall health, age, and availability of donor organs.

Other Physical Treatment Approaches

Some medical centers have experimented with partial lung lavage, a less extensive washing procedure performed under sedation rather than general anesthesia. This approach has been used with some success in Japan, but it requires multiple sessions and has not demonstrated clear advantages over the standard whole lung lavage technique. Most experts continue to recommend whole lung lavage as the preferred physical treatment method.

Physiotherapy, cough-promoting medications, and various respiratory treatments have been tried in patients with alveolar proteinosis, but there is limited evidence supporting their effectiveness as primary treatments. However, breathing exercises and pulmonary rehabilitation programs may help some patients maintain better lung function and manage breathlessness during daily activities.

Innovative Therapies in Clinical Research

Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Therapy

One of the most promising developments in treating autoimmune alveolar proteinosis involves using a naturally occurring protein called granulocyte-macrophage colony stimulating factor, or GM-CSF. This substance plays a crucial role in helping immune cells called macrophages mature and function properly. In autoimmune alveolar proteinosis, the body produces antibodies that block GM-CSF, preventing these cleaning cells from removing excess surfactant from the air sacs.

Researchers have conducted multiple clinical trials investigating whether giving patients additional GM-CSF can overcome this blockade and restore normal lung function. The medication can be administered in two different ways: as a subcutaneous injection under the skin, or as an inhaled mist directly into the lungs. Both methods are being studied, and each has potential advantages.

One form of GM-CSF called sargramostim has been tested in several studies. In a comprehensive analysis combining results from five different trials involving 94 patients with autoimmune alveolar proteinosis, researchers found that response rates ranged from 43 to 92 percent, with an overall pooled response rate of about 59 percent. This means that roughly six out of ten patients experienced some degree of improvement with GM-CSF therapy.

More recent research has produced mixed results. A randomized controlled trial examining inhaled GM-CSF in patients with mild to moderate autoimmune alveolar proteinosis showed only modest improvements in oxygen levels and no significant clinical benefits that patients could feel. However, guidelines published in 2024 by the European Respiratory Society still recommend inhaled GM-CSF as a treatment option for symptomatic patients with confirmed autoimmune disease.

Another form called molgramostim has been specifically developed for delivery through inhalation. This medication is being studied in clinical trials, though as of now it has not yet received approval from the U.S. Food and Drug Administration for treating autoimmune alveolar proteinosis. The availability of these GM-CSF medications varies from country to country, and in some places, doctors may need special permission from national health authorities to prescribe them.

The potential advantage of GM-CSF therapy is that it may reduce or eliminate the need for repeated lung lavage procedures. Some patients might use it as a first-line treatment instead of undergoing whole lung lavage, while others might benefit from GM-CSF to extend the time between lavage procedures. Research continues to determine which patients are most likely to respond well and what the optimal dosing schedules should be.

Targeting the Immune System

Because autoimmune alveolar proteinosis is caused by antibodies that attack the body’s own GM-CSF, some researchers have investigated whether medications that suppress these antibodies might be helpful. One such medication is rituximab, which selectively targets and destroys certain immune cells that produce antibodies.

In a small study involving nine patients treated with rituximab, seven showed decreased levels of anti-GM-CSF antibodies in their lung fluid. The treatment appeared to improve how well the macrophages in their lungs processed fats and proteins, and it increased levels of surfactant proteins. Based on emerging evidence, the 2024 European Respiratory Society guidelines suggest rituximab as a treatment option for patients with confirmed autoimmune alveolar proteinosis who have significant symptoms and need supplemental oxygen despite having undergone whole lung lavage or GM-CSF therapy.

Another approach involves plasmapheresis, a procedure that physically removes antibodies from the bloodstream. During plasmapheresis, blood is drawn from the patient, passed through a machine that separates out the antibody-containing plasma, and then returned to the body with replacement fluid. The European Respiratory Society guidelines also suggest plasmapheresis for severely ill patients who haven’t improved with other treatments. However, more research is needed to determine how effective this approach is and which patients benefit most.

These immune-targeting therapies represent Phase II and Phase III clinical trial developments, meaning researchers are still determining both how well they work and comparing them to standard treatments. The goal is to find out whether modifying the immune system can provide longer-lasting benefits than simply washing out the lungs repeatedly.

Gene Therapy for Genetic Forms

Congenital alveolar proteinosis—the form caused by genetic mutations—presents unique treatment challenges. These patients don’t have antibodies blocking GM-CSF, so giving them extra GM-CSF typically doesn’t help. Instead, their genetic defects affect either the receptors that respond to GM-CSF or the production of surfactant proteins themselves.

Because congenital alveolar proteinosis results from single-gene defects, researchers are exploring whether gene therapy might offer a potential cure. This approach would involve introducing a correct copy of the faulty gene into the patient’s cells, potentially restoring normal lung function. While this research remains in early stages and no gene therapy has yet been approved for alveolar proteinosis, it represents an exciting area of investigation for the future.

Clinical Trial Locations and Participation

Clinical trials for alveolar proteinosis are being conducted at medical centers around the world, including locations in the United States, Europe, and Japan. Patients interested in participating in research studies should discuss this option with their pulmonologist, who can help determine eligibility and provide information about available trials. Participation in clinical trials not only offers access to cutting-edge treatments but also contributes valuable information that helps improve care for future patients with this rare disease.

Most Common Treatment Methods

• Whole Lung Lavage (Physical Treatment)
  • Washing procedure performed under general anesthesia in an operating theater
  • Uses sterile saline to flush accumulated surfactant from one lung at a time
  • Requires specialized double-lumen breathing tube to isolate each lung
  • May involve washing with 30 to 40 liters of saline over several hours
  • Patients typically notice improvement within 24 hours after the procedure
  • Each lung must be treated separately, sometimes requiring two separate hospital admissions
  • Remains the standard of care since 1963 for symptomatic patients
• Oxygen Therapy (Supportive Care)
  • Supplemental oxygen provided at home for patients with low blood oxygen levels
  • May be needed during activity, rest, or sleep depending on disease severity
  • Portable concentrators allow patients to maintain daily activities
  • Critical for preventing complications from chronic low oxygen levels
• GM-CSF Therapy (Immunological Treatment)
  • Granulocyte-macrophage colony stimulating factor administered to restore macrophage function
  • Can be given by subcutaneous injection or inhaled directly into the lungs
  • Sargramostim is one form that has been tested in clinical trials
  • Response rates range from 43 to 92 percent in different studies
  • May be used as first-line alternative to whole lung lavage
  • Helps immune cells clear excess surfactant from air sacs
  • Availability varies by country and may require special authorization
• Rituximab (Immunosuppressive Treatment)
  • Medication that selectively destroys antibody-producing immune cells
  • Reduces anti-GM-CSF antibody levels in lung fluid
  • Improves alveolar macrophage metabolism of fats and proteins
  • Suggested for patients with significant symptoms despite other treatments
  • Recommended for those requiring supplemental oxygen after whole lung lavage or GM-CSF therapy
• Plasmapheresis (Immunological Treatment)
  • Procedure that physically removes antibodies from the bloodstream
  • Blood is processed through a machine to separate out antibody-containing plasma
  • Suggested for severely ill patients who haven’t improved with other treatments
  • More research needed to determine optimal patient selection and effectiveness
• Treatment of Underlying Conditions (For Secondary PAP)
  • Addresses primary diseases causing secondary alveolar proteinosis
  • May involve treating blood disorders like myelodysplastic syndrome
  • Includes managing immune deficiency diseases
  • Requires removing exposure to toxic dusts or chemicals
  • Essential for preventing recurrence after lung lavage
• Lung Transplantation (Advanced Cases)
  • Reserved for patients with severe, progressive disease
  • Considered when respiratory failure occurs despite all other treatments
  • Requires careful evaluation by specialized transplant team
  • Involves consideration of overall health, age, and donor availability

Living with Alveolar Proteinosis

Managing alveolar proteinosis requires ongoing attention to lung health and regular communication with a pulmonary medicine specialist. Patients should contact their healthcare provider immediately if they develop sudden or worsening shortness of breath, chest pain, fever, or other new symptoms. These signs could indicate a lung infection or other complication requiring prompt treatment.

Smoking cessation is absolutely critical for anyone with this lung disease. Smoking damages the lungs further and increases the risk of infections and other complications. While smoking has been associated with higher rates of alveolar proteinosis, quitting can help protect remaining lung function and improve response to treatment.

Regular follow-up appointments allow doctors to monitor disease progression through pulmonary function tests, blood oxygen measurements, imaging studies, and other diagnostic tests. These evaluations help determine when additional treatments might be needed and whether current therapies are working effectively.

Many patients find support through patient foundations and organizations dedicated to rare lung diseases. Connecting with others who understand the challenges of living with alveolar proteinosis can provide emotional support, practical advice, and information about the latest research developments. The PAP Foundation and similar organizations offer resources for patients and families dealing with this rare condition.

With appropriate treatment and careful monitoring, many patients with alveolar proteinosis can maintain good quality of life. The five-year survival rate with treatment is approximately 80 percent, and some patients remain stable for many years. While there is currently no cure, ongoing research continues to improve understanding of this rare disease and develop better treatment approaches.